HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Joseph B. Shrager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shrager, J. B. Search for Related Content PubMed Articles by Shrager, J. B. Related Collections Lung - other

Ann Thorac Surg 2004;77:1895
© 2004 The Society of Thoracic Surgeons

Invited commentary

Department of Surgery University of Pennsylvania Health System 4th Floor Silverstein 3400 Spruce St Philadelphia, PA 19104-4283, USA

e-mail: jshrag@mail.med.upenn.edu

The first 20% of the full text of this article appears below.

This paper by Iyoda et al sheds further light on a subtype of bronchogenic carcinoma that has been poorly understood by surgeons and pathologists alike. Large cell neuroendocrine carcinoma (LCNEC) makes up approximately 2–3% of non-small cell lung cancers (NSCLC). However, until the World Health Organization (WHO) formally reclassified pulmonary tumors with neuroendocrine morphology in its 1999 Histological Typing of Lung and Pleural Tumors, the use of widely variable terminologies and criteria for diagnosing LCNEC hindered progress in understanding this tumor.

As defined by the WHO, LCNEC lies with small cell carcinoma (SCLC) at the high-grade end of the spectrum of tumors with neuroendocrine morphology—a spectrum that also includes typical and atypical carcinoids. The diagnosis of LCNEC requires not only the presence of neuroendocrine histological features on . . . [Full Text of this Article]